PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CRL vs. WAT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CRL and WAT is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

CRL vs. WAT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Charles River Laboratories International, Inc. (CRL) and Waters Corporation (WAT). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%AugustSeptemberOctoberNovemberDecember2025
-24.03%
31.37%
CRL
WAT

Key characteristics

Sharpe Ratio

CRL:

-0.53

WAT:

0.86

Sortino Ratio

CRL:

-0.58

WAT:

1.67

Omega Ratio

CRL:

0.93

WAT:

1.20

Calmar Ratio

CRL:

-0.31

WAT:

0.87

Martin Ratio

CRL:

-0.88

WAT:

3.18

Ulcer Index

CRL:

22.44%

WAT:

9.17%

Daily Std Dev

CRL:

37.33%

WAT:

33.94%

Max Drawdown

CRL:

-69.81%

WAT:

-80.12%

Current Drawdown

CRL:

-63.82%

WAT:

-6.36%

Fundamentals

Market Cap

CRL:

$8.89B

WAT:

$23.61B

EPS

CRL:

$8.02

WAT:

$10.50

PE Ratio

CRL:

21.68

WAT:

37.88

PEG Ratio

CRL:

2.30

WAT:

3.81

Total Revenue (TTM)

CRL:

$3.05B

WAT:

$2.09B

Gross Profit (TTM)

CRL:

$1.00B

WAT:

$1.20B

EBITDA (TTM)

CRL:

$667.60M

WAT:

$691.56M

Returns By Period

In the year-to-date period, CRL achieves a -10.18% return, which is significantly lower than WAT's 7.20% return. Over the past 10 years, CRL has underperformed WAT with an annualized return of 9.31%, while WAT has yielded a comparatively higher 13.40% annualized return.


CRL

YTD

-10.18%

1M

-12.43%

6M

-24.15%

1Y

-18.53%

5Y*

0.74%

10Y*

9.31%

WAT

YTD

7.20%

1M

6.33%

6M

26.50%

1Y

29.07%

5Y*

10.71%

10Y*

13.40%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CRL vs. WAT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRL
The Risk-Adjusted Performance Rank of CRL is 2323
Overall Rank
The Sharpe Ratio Rank of CRL is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of CRL is 1919
Sortino Ratio Rank
The Omega Ratio Rank of CRL is 2020
Omega Ratio Rank
The Calmar Ratio Rank of CRL is 2929
Calmar Ratio Rank
The Martin Ratio Rank of CRL is 2828
Martin Ratio Rank

WAT
The Risk-Adjusted Performance Rank of WAT is 7575
Overall Rank
The Sharpe Ratio Rank of WAT is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of WAT is 7676
Sortino Ratio Rank
The Omega Ratio Rank of WAT is 7272
Omega Ratio Rank
The Calmar Ratio Rank of WAT is 7878
Calmar Ratio Rank
The Martin Ratio Rank of WAT is 7575
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CRL vs. WAT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and Waters Corporation (WAT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CRL, currently valued at -0.53, compared to the broader market-2.000.002.00-0.530.86
The chart of Sortino ratio for CRL, currently valued at -0.58, compared to the broader market-4.00-2.000.002.004.006.00-0.581.67
The chart of Omega ratio for CRL, currently valued at 0.93, compared to the broader market0.501.001.502.000.931.20
The chart of Calmar ratio for CRL, currently valued at -0.31, compared to the broader market0.002.004.006.00-0.310.87
The chart of Martin ratio for CRL, currently valued at -0.88, compared to the broader market-10.000.0010.0020.0030.00-0.883.17
CRL
WAT

The current CRL Sharpe Ratio is -0.53, which is lower than the WAT Sharpe Ratio of 0.86. The chart below compares the historical Sharpe Ratios of CRL and WAT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
-0.53
0.86
CRL
WAT

Dividends

CRL vs. WAT - Dividend Comparison

Neither CRL nor WAT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CRL vs. WAT - Drawdown Comparison

The maximum CRL drawdown since its inception was -69.81%, smaller than the maximum WAT drawdown of -80.12%. Use the drawdown chart below to compare losses from any high point for CRL and WAT. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-63.82%
-6.36%
CRL
WAT

Volatility

CRL vs. WAT - Volatility Comparison

Charles River Laboratories International, Inc. (CRL) has a higher volatility of 9.99% compared to Waters Corporation (WAT) at 7.76%. This indicates that CRL's price experiences larger fluctuations and is considered to be riskier than WAT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%AugustSeptemberOctoberNovemberDecember2025
9.99%
7.76%
CRL
WAT

Financials

CRL vs. WAT - Financials Comparison

This section allows you to compare key financial metrics between Charles River Laboratories International, Inc. and Waters Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab